The Cutting-Edge Regenerative Therapy You've Probably Never Heard Of — And It's a Real Game-Changer
Imagine a treatment with no surgery, no needles, and no downtime — one that uses your own body's healing response to relieve joint and tendon pain, restore blood flow, and improve sexual function for both men and women. It sounds almost too good to be true. But it's backed by a genuine and growing body of clinical research, and it's called GAINSWave.
At Full Spectrum Integrative Medicine in Devon, PA, we've added GAINSWave to our regenerative therapy toolkit because it does something rare in medicine: one technology with multiple real applications and compelling evidence behind each one.
What Is GAINSWave?
GAINSWave is built on low-intensity extracorporeal shockwave therapy (LI-ESWT) — high-frequency acoustic sound waves delivered directly to targeted tissue. The underlying shockwave technology is FDA-cleared and backed by decades of research.
Here's what's actually happening in your body: the acoustic waves trigger mechanotransduction, essentially "waking up" cells at a biological level. This stimulates angiogenesis (new blood vessel growth), activates fibroblasts that repair damaged tissue, boosts collagen production, and dramatically improves circulation to the treated area (De la Corte-Rodríguez et al., Healthcare, 2023). It doesn't mask a problem — it switches on your body's own ability to regenerate healthier tissue.
Where the Evidence Is Strongest: Musculoskeletal Pain
This might be the most surprising part: the same technology used for sexual wellness is also one of the most rigorously studied non-surgical treatments available for musculoskeletal pain. A 2023 review gave shockwave therapy its highest possible evidence rating for calcific shoulder tendinopathy, tennis elbow, plantar fasciitis, and delayed bone healing, with strong evidence also supporting Achilles and patellar tendinopathy, osteoarthritis, and carpal tunnel syndrome — with benefits that can last up to two years (De la Corte-Rodríguez et al., Healthcare, 2023).
A 2024 meta-analysis of 11 randomized controlled trials on plantar fasciitis found significant pain reduction with an outstanding safety record: over 90% of patients completed treatment, with only mild, temporary side effects like local redness or bruising (European Journal of Physical and Rehabilitation Medicine, 2024). That's a remarkable combination of effectiveness and safety for a non-invasive therapy.
For Men: Real, Measurable Results for ED and Peyronie's Disease
A 2022 meta-analysis of 16 randomized controlled trials found that low-intensity shockwave therapy produced statistically significant improvements in erectile function scores at one, three, and six months, with especially strong results for men with moderate ED (Yao et al., American Journal of Men's Health, 2022). Men treated were significantly more likely to regain the erectile hardness needed for intercourse — with more than five times the odds in the pooled analysis (odds ratio 5.07).
For Peyronie's disease, a 2024 meta-analysis found meaningful reductions in penile plaque size, improved curvature, and complete pain remission in a substantial number of men (BMC Urology, 2024) — a real, tangible win for a condition that's historically been hard to treat non-surgically.
For Women: An Exciting, Fast-Moving Frontier
Women's sexual health has long been under-researched compared to men's, and that's finally starting to change. Early clinical data presented at meetings of the International Continence Society and the International Society for Sexual Medicine has shown encouraging results for women experiencing decreased sensation, difficulty with arousal, and stress urinary incontinence. This research base is newer, but it rests on the same powerful biology that drives the men's health results: improved blood flow and tissue responsiveness.
An Exciting Off-Label Use: Neuropathy
One application worth getting excited about: neuropathy. GAINSWave isn't FDA-cleared specifically for nerve pain, but the science behind it is compelling. A 2023 study found shockwave therapy significantly restored blood flow in diabetic feet, with tissue oxygen levels recovering to healthy thresholds within just two weeks of treatment (Jeong et al., Medicine, 2023) — and poor circulation is a major driver of neuropathy. A 2024 review also found shockwave therapy improved nerve conduction, likely by boosting nerve growth factor and blood flow to nerve tissue (Meng et al., Frontiers in Neurology, 2024). For people who haven't found relief through conventional routes, this is a low-risk option well worth exploring with a provider.
How FSIM Maximizes Results: Combination Protocols
GAINSWave is an in-office treatment at FSIM — short 15- to 20-minute sessions, 1 to 2 times a week, over a course of 3 to 12 weeks depending on the condition. And we don't stop there: we've built protocols that pair GAINSWave with the other tools in our practice — targeted supplements, red light therapy, hormone optimization, medications when appropriate, PRP when it's a good fit, and acupuncture or a guided exercise plan — all tailored to what each patient's body needs. That's the "full spectrum" philosophy in action, and it's how we help patients get the most out of every session.
Why We Offer It at Full Spectrum Integrative Medicine
At FSIM, we practice integrative and functional medicine — treating the whole person and addressing root causes, not just symptoms. GAINSWave fits that philosophy perfectly: non-invasive, regenerative, and backed by real evidence across musculoskeletal pain, men's sexual health, and women's sexual wellness. It's one of the most versatile, genuinely evidence-based tools in our practice today.
If you've been living with joint or tendon pain, ED, Peyronie's symptoms, or changes in sexual function and haven't found real answers yet, this is well worth exploring.
Curious whether GAINSWave is right for you? Email us at Hello@FullSpectrumIM.com or call 610-557-8500 to schedule an evaluation with Dr. Rashna Staid at Full Spectrum Integrative Medicine in Devon, PA.
Medical References
De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, Vázquez-Sasot A, Rodríguez-Merchán EC. Extracorporeal Shock Wave Therapy for the Treatment of Musculoskeletal Pain: A Narrative Review. Healthcare (Basel). 2023;11(21):2830. https://www.mdpi.com/2227-9032/11/21/2830
Yao H, Wang X, Liu H, Sun F, Tang G, Bao X, Wu J, Zhou Z, Ma J. Systematic Review and Meta-Analysis of 16 Randomized Controlled Trials of Clinical Outcomes of Low-Intensity Extracorporeal Shock Wave Therapy in Treating Erectile Dysfunction. American Journal of Men's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35319291/
Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a systematic review and meta-analysis. BMC Urology. 2024. https://link.springer.com/article/10.1186/s12894-024-01607-4
Efficacy and tolerability of extracorporeal shock wave therapy in patients with plantar fasciopathy: a systematic review with meta-analysis and meta-regression. European Journal of Physical and Rehabilitation Medicine. 2024;60(5):832-846. https://pmc.ncbi.nlm.nih.gov/articles/PMC11561739/
ICS 2021 Abstract #452 — Large Area Low Intensity Shockwave (LALIS) Therapy for Treating Women's Stress Urinary Incontinence and Sexual Dysfunction. International Continence Society. https://www.ics.org/2021/abstract/452
Low Intensity Shockwave Therapy for Women with Sexual Dysfunction. The Journal of Sexual Medicine. Oxford Academic. https://academic.oup.com/jsm/article/21/Supplement_5/qdae054.093/7694148
Jeong JY, et al. Application of extracorporeal shockwave therapy to improve microcirculation in diabetic foot ulcers: A prospective study. Medicine (Baltimore). 2023;102(11). https://pmc.ncbi.nlm.nih.gov/articles/PMC10019234
Meng D, et al. Effect of extracorporeal shock wave therapy on nerve conduction: a systematic review and meta-analysis. Frontiers in Neurology. 2024. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1493692/full
GAINSWave® technology overview. GAINSWave. https://gainswave.com
This blog post is for educational purposes and does not replace an individualized medical evaluation.
Comments